Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The term "ganirelix + cetrorelix" refers to a pooled comparator group of two injectable gonadotropin-releasing hormone (GnRH) antagonists used in controlled ovarian stimulation (COS) for in vitro fertilization (IVF). Both ganirelix and cetrorelix are synthetic decapeptides that competitively bind to GnRH receptors in the pituitary gland. This binding leads to the rapid suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby preventing premature LH surges and ovulation during the stimulation phase. In clinical trial contexts, such as those sponsored by Centro A.M.B.R.A., these agents serve as the standard-of-care active comparator against novel oral GnRH antagonists like linzagolix.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ganirelix + cetrorelix.